PriceTargets.com logo

Actuate Therapeutics - ACTU Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.50
  • Forecasted Upside: 157.21%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.97 As of 06/18/2025 12:36 PM ET
▲ +0.2 (2.57%)

This chart shows the closing price for ACTU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Actuate Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACTU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACTU

Analyst Price Target is $20.50
▲ +157.21% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Actuate Therapeutics in the last 3 months. The average price target is $20.50, with a high forecast of $21.00 and a low forecast of $20.00. The average price target represents a 157.21% upside from the last price of $7.97.

This chart shows the closing price for ACTU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Actuate Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/3/2025HC WainwrightBoost TargetBuy$20.00
4/22/2025Craig HallumInitiated CoverageBuy$21.00
3/17/2025HC WainwrightInitiated CoverageBuy$20.00
(Data available from 6/18/2020 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/19/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2025
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2025

Current Sentiment

  • 3 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Actuate Therapeutics logo
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Read More

Today's Range

Now: $7.97
Low: $7.59
High: $8.09

50 Day Range

MA: $9.30
Low: $7.11
High: $11.36

52 Week Range

Now: $7.97
Low: $5.51
High: $11.99

Volume

11,681 shs

Average Volume

49,181 shs

Market Capitalization

$156.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Actuate Therapeutics?

The following Wall Street research analysts have issued research reports on Actuate Therapeutics in the last twelve months: Craig Hallum, and HC Wainwright.
View the latest analyst ratings for ACTU.

What is the current price target for Actuate Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Actuate Therapeutics in the last year. Their average twelve-month price target is $20.50, suggesting a possible upside of 163.8%. Craig Hallum has the highest price target set, predicting ACTU will reach $21.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $20.00 for Actuate Therapeutics in the next year.
View the latest price targets for ACTU.

What is the current consensus analyst rating for Actuate Therapeutics?

Actuate Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACTU will outperform the market and that investors should add to their positions of Actuate Therapeutics.
View the latest ratings for ACTU.

What other companies compete with Actuate Therapeutics?

Other companies that are similar to Actuate Therapeutics include KalVista Pharmaceuticals, Xencor, Evolus, Stoke Therapeutics and Sionna Therapeutics. Learn More about companies similar to Actuate Therapeutics.

How do I contact Actuate Therapeutics' investor relations team?

Actuate Therapeutics' physical mailing address is 1751 RIVER RUN, SUITE 400, FORT WORTH, TX, 76107. The company's listed phone number is (847) 986-4190 and its investor relations email address is [email protected]. The official website for Actuate Therapeutics is actuatetherapeutics.com. Learn More about contacing Actuate Therapeutics investor relations.